Drugs Containing Excipient (Inactive Ingredient) DEHYDROACETIC ACID

« Back to Dashboard

Generic drugs containing DEHYDROACETIC ACID excipient

Company	Ingredient	NDC	Excipient
Padagis Israel Pharmaceuticals Ltd	hydrocortisone	45802-937	DEHYDROACETIC ACID
Physicians Total Care Inc	hydrocortisone	54868-5893	DEHYDROACETIC ACID
Bryant Ranch Prepack	hydrocortisone	63629-2529	DEHYDROACETIC ACID
Bryant Ranch Prepack	hydrocortisone	63629-8668	DEHYDROACETIC ACID
Bryant Ranch Prepack	hydrocortisone	63629-9416	DEHYDROACETIC ACID
Bryant Ranch Prepack	hydrocortisone	71335-2918	DEHYDROACETIC ACID
Bryant Ranch Prepack	hydrocortisone	72162-1441	DEHYDROACETIC ACID

Dehydroacetic Acid Market Dynamics and Financial Trajectory

Last updated: August 29, 2026

Dehydroacetic acid is a niche antimicrobial preservative used mainly in cosmetics, personal care products, and selected industrial formulations. Its pharmaceutical-excipient market is small and fragmented, with no reliable public revenue series for the substance itself. Commercial performance is driven more by cosmetic-preservative demand, regional regulatory limits, supplier concentration, and substitution risk than by prescription-drug volume.

The near-term outlook is stable but constrained. Dehydroacetic acid benefits from demand for preservative systems in creams, lotions, shampoos, color cosmetics, and other water-containing formulations. Growth is limited by regulatory restrictions, consumer preference for "preservative-free" or naturally positioned products, and competition from potassium sorbate, sodium benzoate, phenoxyethanol, organic acids, multifunctional glycols, and newer preservation systems.

What is dehydroacetic acid and how is it used?

Dehydroacetic acid, also known as DHA or dehydroacetic acid, is an organic compound with the following identifiers:

Attribute	Data
Chemical name	Dehydroacetic acid
CAS number	520-45-6
Molecular formula	C8H8O4
Molecular weight	168.15 g/mol
Chemical class	Pyrone-derived organic acid
Principal function	Antimicrobial preservative
Common related material	Sodium dehydroacetate
Main commercial sectors	Cosmetics, personal care, coatings, selected formulations
Pharmaceutical role	Specialty preservative or formulation ingredient, not a major systemic-drug excipient

Dehydroacetic acid is generally supplied as a white crystalline powder. Its commercial value comes from antimicrobial activity at low concentrations, compatibility with certain oil-in-water and emulsion systems, and use in preservative blends.

Its practical application is narrower than that of phenoxyethanol or parabens. Formulators often use it in combination with other preservatives because its performance depends on pH, solubility, formulation composition, packaging, and microbial challenge conditions.

PubChem identifies dehydroacetic acid as a preservative-related chemical with applications extending beyond pharmaceuticals and cosmetics.[1]

How large is the dehydroacetic acid market?

No major producer publicly reports dehydroacetic acid revenue as a separate line item. Published market studies generally combine it with broader categories such as cosmetic preservatives, organic preservatives, specialty chemicals, or personal-care ingredients. Those aggregated figures cannot support a defensible standalone market-size estimate.

The commercial market has four defining characteristics:

1. It is a niche-volume specialty chemical.
2. It is fragmented across regional manufacturers and distributors.
3. Demand is concentrated in cosmetics and personal care rather than finished pharmaceuticals.
4. Pricing is affected by manufacturing scale and regulatory documentation more than by patent exclusivity.

The pharmaceutical-excipient segment is likely materially smaller than the cosmetic and personal-care segment. Pharmaceutical applications require stronger documentation covering identity, purity, residual solvents, elemental impurities, microbial quality, change control, and supply continuity. Those requirements raise qualification costs and favor suppliers with established quality systems.

What drives demand?

Demand depends on:

• Growth in creams, lotions, shampoos, makeup, and wet wipes.
• Expansion of water-based cosmetic formulations.
• Demand for low-dose preservation systems.
• Product launches in emerging personal-care markets.
• Reformulation away from formaldehyde donors and certain parabens.
• Distributor inventory cycles.
• Regulatory acceptance in the destination market.

Demand is less connected to prescription-drug growth. A pharmaceutical manufacturer may use dehydroacetic acid in a topical or semisolid product, but a single formulation change can remove the ingredient from a product line.

What is the financial trajectory for dehydroacetic acid?

The financial trajectory is best described as stable-to-low growth in volume, with greater volatility in margins and regional pricing.

Period	Expected commercial pattern	Main financial effects
Historical base	Mature specialty-preservative demand	Established applications, price competition
Near term	Low single-digit volume growth in personal care	Inflation recovery offset by substitution
Medium term	Mixed regional growth	Emerging-market demand versus tighter regulation
Long term	Flat-to-low growth in the pharmaceutical-excipient niche	Qualification barriers support suppliers, but alternative preservatives limit expansion

A precise dollar forecast is not available from public company filings or regulatory databases. The substance is usually embedded within broader specialty-chemical revenue categories. Supplier earnings therefore cannot be attributed reliably to dehydroacetic acid.

What determines supplier profitability?

Supplier economics depend on five factors:

• Feedstock and energy costs.
• Production scale.
• Purity and particle-size specifications.
• Regulatory documentation.
• Customer qualification and switching costs.

The product is not generally differentiated by a strong proprietary patent position. Margin protection instead comes from manufacturing reliability, low contamination rates, validated analytical methods, technical support, and customer approval status.

A supplier selling technical-grade material into industrial applications may compete primarily on price. A supplier selling into pharmaceutical or high-end cosmetic applications can command a premium when it provides audited manufacturing, batch consistency, traceability, and regulatory support.

Which industries account for most dehydroacetic acid demand?

Cosmetics and personal care

Cosmetics and personal care are the principal demand centers. Applications include:

• Skin creams and lotions.
• Hair products.
• Color cosmetics.
• Cleansing products.
• Wet formulations.
• Deodorants and related products.
• Some natural-positioned formulations that accept synthetic preservatives.

The cosmetics sector values broad supplier availability and formulation flexibility. It also creates substitution risk because brand owners may remove or replace preservatives for marketing reasons even when the incumbent ingredient remains legally permitted.

Pharmaceutical formulations

Pharmaceutical use is more limited and product-specific. Potential applications include topical creams, gels, lotions, and other nonsterile semisolid products where microbial control is required.

The FDA Inactive Ingredient Database is the relevant U.S. reference for determining whether a substance has precedent as an inactive ingredient in approved drug products. Presence in the database does not create market exclusivity and does not guarantee acceptance in a new formulation.[2]

A sponsor must still establish:

• Compatibility with the active pharmaceutical ingredient.
• Preservation efficacy.
• Stability over the proposed shelf life.
• Absence of unacceptable degradation products.
• Suitability for the route of administration.
• Compliance with applicable compendial and regulatory expectations.

Industrial and other uses

Dehydroacetic acid and related salts can also appear in industrial preservation systems, coatings, adhesives, and other materials. These markets can absorb volume but generally generate lower prices than pharmaceutical or premium personal-care applications.

What is the regulatory status of dehydroacetic acid?

United States

In the United States, dehydroacetic acid is primarily relevant to cosmetics and formulation-specific drug products. Cosmetics generally do not require FDA premarket approval, except for color additives and certain restricted categories. Manufacturers remain responsible for product safety and labeling under the Federal Food, Drug, and Cosmetic Act and the Modernization of Cosmetics Regulation Act.

For drugs, the substance must be evaluated as an inactive ingredient in the context of the specific dosage form, route, concentration, and product design. The FDA Inactive Ingredient Database is a key reference, but it does not function as a blanket authorization for all uses.[2]

European Union

The European Union regulates cosmetic preservatives under Annex V of Regulation (EC) No. 1223/2009. Dehydroacetic acid and its salts are subject to specified conditions, including concentration limits and product-use restrictions.[3]

EU compliance requires a responsible person, product information file, safety assessment, ingredient labeling, and notification through the Cosmetic Products Notification Portal. A regulatory change affecting permitted concentration or product category can reduce addressable demand quickly.

Other jurisdictions

China, Japan, South Korea, Canada, Australia, and ASEAN markets maintain their own cosmetic and pharmaceutical requirements. Suppliers selling internationally must control:

• Country-specific preservative permissions.
• Maximum-use concentrations.
• Prohibited product categories.
• Import documentation.
• Safety data sheets.
• Good manufacturing practice records.
• Language and labeling requirements.

How strong is the patent estate for dehydroacetic acid?

The underlying compound is an established chemical and is not protected by a meaningful new-molecule patent estate. The commercial IP position is therefore weaker than for a patented active pharmaceutical ingredient.

Potentially relevant IP may cover:

• Manufacturing processes.
• Purification methods.
• Particle engineering.
• Preservative combinations.
• Specific cosmetic formulations.
• Delivery systems.
• Stability-enhancing excipient blends.
• Drug-product compositions containing dehydroacetic acid.

These rights are generally formulation- or process-specific. They do not create broad exclusivity over the compound itself.

What patent litigation affects dehydroacetic acid?

There is no widely recognized Orange Book patent dispute or major Paragraph IV litigation centered on dehydroacetic acid as an excipient. The FDA Orange Book lists approved drug products and patents submitted by applicants; it is not a general registry for commodity excipients.[4]

For this ingredient, litigation risk is more likely to arise from:

• A proprietary topical formulation.
• A combination-preservative system.
• A manufacturing process.
• Trade-secret allegations.
• Contract disputes involving specification, supply, or change control.

When does dehydroacetic acid lose exclusivity?

Dehydroacetic acid has no relevant compound-level exclusivity timetable comparable to a new drug. There is no standard Hatch-Waxman loss-of-exclusivity date for the substance as a commodity excipient.

The commercial exposure is instead tied to the protected drug product or cosmetic formulation. If a company owns a formulation patent, exclusivity depends on the claims, filing date, patent term adjustment, terminal disclaimers, and jurisdiction. If the ingredient is used in an approved drug without a valid formulation patent, competitors can generally use the same excipient subject to regulatory and quality requirements.

What alternatives compete with dehydroacetic acid?

Alternative	Competitive advantage	Limitation
Phenoxyethanol	Broad use, strong supplier base, familiar regulatory profile	Consumer resistance in some markets
Sodium benzoate	Low cost, established use	Strongly pH-dependent
Potassium sorbate	Familiar food and cosmetic preservative	Limited performance at higher pH
Benzyl alcohol	Preservative and solvent functionality	Odor, sensitization, and formulation limits
Parabens	Effective and inexpensive	Consumer and regional regulatory pressure
Organic-acid blends	Natural-positioning potential	pH and formulation sensitivity
Multifunctional glycols	Humectancy plus preservation support	May require combination systems
Caprylyl glycol systems	Marketing and emollient benefits	Higher cost and variable efficacy

Dehydroacetic acid is strongest when a formulator needs a powder preservative with acceptable compatibility in a particular emulsion or topical system. It is weaker when the product is marketed around "clean beauty," minimal ingredients, or naturally derived preservation.

What manufacturing and supply-chain barriers exist?

Manufacturing barriers are moderate, not prohibitive. The compound does not require biologic production, aseptic processing, or complex molecular engineering. Capacity can be established by specialty-chemical manufacturers with suitable synthesis, crystallization, drying, and quality-control infrastructure.

The more important barriers are commercial and regulatory:

• Customer qualification periods.
• Batch-to-batch consistency.
• Impurity control.
• Reliable export documentation.
• Technical support.
• Change-notification obligations.
• Registration in multiple jurisdictions.
• Limited substitution tolerance in validated pharmaceutical products.

Supply-chain risk rises when buyers depend on a small number of Asian producers or a single qualified manufacturing site. A technical-grade replacement may be readily available, while a pharmaceutical-grade replacement can require audits, method transfer, stability work, and regulatory assessment.

Which companies are challenging the dehydroacetic acid market?

Competition is fragmented. The principal competitive groups are:

1. Asian specialty-chemical manufacturers producing dehydroacetic acid or sodium dehydroacetate.
2. Global ingredient distributors carrying multiple preservative systems.
3. Large cosmetic-ingredient suppliers selling formulation packages rather than single chemicals.
4. Producers of competing preservatives and multifunctional ingredients.
5. Contract manufacturers with proprietary preservation platforms.

Public-company financial statements generally do not identify dehydroacetic acid sales separately. As a result, market share rankings and supplier revenue estimates require paid trade data, customs analysis, or direct company disclosures.

What licensing deals and settlement agreements affect the market?

No major public licensing transaction or settlement agreement is broadly associated with dehydroacetic acid as a standalone excipient. Commercial arrangements are more likely to involve:

• Regional distribution rights.
• Private-label supply.
• Toll manufacturing.
• Quality agreements.
• Long-term procurement contracts.
• Formulation licenses containing a broader preservative system.

These agreements can affect a supplier's regional access but generally do not create market-wide exclusivity.

What generic entry risks exist for pharmaceutical products using dehydroacetic acid?

Generic entry risk is determined by the finished drug product, not by the excipient alone. A generic applicant can often use the same preservative if it can match the reference product's quality, stability, performance, and regulatory requirements.

Key risk factors include:

• Whether the preservative is disclosed in the reference product.
• Whether the product is a topical semisolid with complex formulation behavior.
• Whether the reference sponsor owns formulation patents.
• Whether the preservative concentration affects bioavailability or local tolerability.
• Whether a generic manufacturer can reproduce preservative efficacy.
• Whether the product has a narrow therapeutic index or sensitive active ingredient.

For simple topical products, excipient replication may reduce entry barriers. For complex emulsions, gels, or combination products, formulation development remains a meaningful barrier even when the preservative itself is unprotected.

What is the commercial outlook?

The base case is a mature, defensible niche with modest growth and limited pricing power. Personal-care demand should remain the primary revenue source. Pharmaceutical-excipient demand can provide higher margins but is unlikely to transform total market size unless a major product adopts dehydroacetic acid at scale.

Base case

Volume grows slowly as personal-care consumption expands in emerging markets. Prices remain competitive, with periodic increases caused by raw-material, energy, freight, or compliance costs.

Upside case

Demand improves if formulators seek alternatives to parabens, formaldehyde donors, or certain preservatives while retaining synthetic, low-dose systems. Growth would be strongest in topical personal care and selected dermatology products.

Downside case

Demand contracts if regulators tighten permitted concentrations, major brands remove the ingredient for marketing reasons, or multifunctional alternatives displace standalone preservation systems.

Key Takeaways

• Dehydroacetic acid is a niche preservative, not a major pharmaceutical excipient.
• Cosmetics and personal care generate most demand.
• No reliable public standalone revenue or market-share series exists.
• The financial outlook is stable to low growth, with margin volatility from supply and regulatory factors.
• Compound-level patent protection is not the primary commercial barrier.
• Formulation, process, and combination patents may remain relevant for specific products.
• There is no standard Orange Book or Paragraph IV exclusivity timeline for dehydroacetic acid itself.
• Regulatory permissions, customer qualification, quality documentation, and supply reliability determine commercial value.
• Competition from phenoxyethanol, benzoates, sorbates, parabens, organic acids, and multifunctional glycols limits pricing power.
• Pharmaceutical upside exists but is unlikely to outweigh the ingredient's broader dependence on cosmetics and personal care.

FAQs

Is dehydroacetic acid approved as a pharmaceutical excipient?

Its acceptability depends on the dosage form, route, concentration, and jurisdiction. The FDA Inactive Ingredient Database is the principal U.S. reference for prior inactive-ingredient use, but database listing does not authorize every proposed application.[2]

Is sodium dehydroacetate different from dehydroacetic acid?

Yes. Sodium dehydroacetate is the salt form. It can have different solubility, handling, formulation performance, and regulatory treatment from the free acid.

Is dehydroacetic acid allowed in EU cosmetics?

It is regulated under Annex V of the EU Cosmetics Regulation and is subject to concentration and product-use conditions.[3]

Does dehydroacetic acid have a pharmaceutical patent cliff?

No. The substance itself does not have a conventional pharmaceutical patent cliff. Patent risk arises from particular drug products, formulations, preservative combinations, or manufacturing methods.

Is dehydroacetic acid a high-margin specialty chemical?

It can generate higher margins in pharmaceutical-grade and documentation-intensive applications, but commodity and technical-grade sales are exposed to price competition and substitution.

References

1. National Center for Biotechnology Information. (n.d.). Dehydroacetic acid. PubChem Compound Summary. https://pubchem.ncbi.nlm.nih.gov/compound/Dehydroacetic-acid

2. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

3. European Parliament and Council of the European Union. (2009). Regulation (EC) No. 1223/2009 on cosmetic products, Annex V. EUR-Lex. https://eur-lex.europa.eu/eli/reg/2009/1223/oj

4. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm